NasdaqGS:ROIVBiotechs
The Bull Case For Roivant Sciences (ROIV) Could Change Following Brepocitinib’s Priority Review In Dermatomyositis
Priovant Therapeutics, linked to Roivant Sciences, previously announced that the U.S. FDA had accepted its New Drug Application for brepocitinib in dermatomyositis and granted Priority Review, setting a PDUFA action date in the third quarter of 2026 and targeting a potential launch by the end of September 2026 if approved.
If approved, brepocitinib would become the first targeted therapy for dermatomyositis, potentially reinforcing Roivant’s positioning in immune-mediated rare diseases and...